Gefitinib for advanced non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Gefitinib for advanced or metastatic non-small cell lung cancer.
Gefitinib is approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed prior platinum-based treatment and docetaxel chemotherapy. Its efficacy when compared to standard treatment and best supportive care is unproven. Common drug-related adverse effects include gastrointestinal and skin disorders. Rare but serious d...
متن کاملGefitinib monotherapy in advanced non-small cell lung cancer: Experience from a large, Western community, implementation study. Running title: Gefitinib for advanced non-small cell lung cancer (NSCLC)
Authors: R. van Puijenbroek, L. Bosquée, A-P. Meert, D. Schallier, J-C. Goeminne, G. Tits, P. Collard, K. Nackaerts, J-L Canon, F. Duplaquet, D. Galdermans, P. Germonpré, M-A. Azerad, G. Vandenhoven, J. De Greve, J. Vansteenkiste. Affiliations: Univ. Hospital, Catholic University, Leuven Citadelle Hospital, Liège Jules Bordet Institute, Brussels Univ. Hopsital VUB, Brussels St-Elisabeth Hospita...
متن کاملGefitinib in Non Small Cell Lung Cancer
Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most common adverse events. The positive results obtained in early phase 2 clinical trials with gefit...
متن کاملGefitinib for the treatment of non-small-cell lung cancer.
IMPORTANCE OF THE FIELD The epidermal growth factor receptor (EGFR) is a leading target for treatment of non-small-cell lung cancer (NSCLC). Recent trials of the small-molecule EGFR inhibitor gefitinib have now more clearly defined indications for usage, and clinical and molecular factors predictive of benefit. AREAS COVERED IN THIS REVIEW A systematic search of the literature (Medline, ASCO,...
متن کاملCurative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients.
OBJECTIVE Gefitinib is effective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) for advanced non-small cell lung cancer (NSCLC) patients, but with the drug use, inevitable gefitinib-resistance and severe complications were observed and resulted in failure treatments. The purpose of the present study was to investigate the curative effect of different treatment of navelbi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2018
ISSN: 1465-1858
DOI: 10.1002/14651858.cd006847.pub2